- Home
- IMVT vs VCYT Comparison
IMVT vs VCYT Comparison
Compare IMVT & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- VCYT
- Stock Information
- Founded
- IMVT 2018
- VCYT 2006
- Country
- IMVT United States
- VCYT United States
- Employees
- IMVT N/A
- VCYT N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- VCYT Medical Specialities
- Sector
- IMVT Health Care
- VCYT Health Care
- Exchange
- IMVT Nasdaq
- VCYT Nasdaq
- Market Cap
- IMVT 2.7B
- VCYT 2.4B
- IPO Year
- IMVT N/A
- VCYT 2013
- Fundamental
- Price
- IMVT $15.24
- VCYT $31.00
- Analyst Decision
- IMVT Buy
- VCYT Buy
- Analyst Count
- IMVT 11
- VCYT 9
- Target Price
- IMVT $35.88
- VCYT $39.89
- AVG Volume (30 Days)
- IMVT 1.2M
- VCYT 2.2M
- Earning Date
- IMVT 08-11-2025
- VCYT 08-06-2025
- Dividend Yield
- IMVT N/A
- VCYT N/A
- EPS Growth
- IMVT N/A
- VCYT N/A
- EPS
- IMVT N/A
- VCYT 0.34
- Revenue
- IMVT N/A
- VCYT $479,129,000.00
- Revenue This Year
- IMVT N/A
- VCYT $12.57
- Revenue Next Year
- IMVT N/A
- VCYT $10.23
- P/E Ratio
- IMVT N/A
- VCYT $92.65
- Revenue Growth
- IMVT N/A
- VCYT 19.91
- 52 Week Low
- IMVT $12.72
- VCYT $22.61
- 52 Week High
- IMVT $34.47
- VCYT $47.32
- Technical
- Relative Strength Index (RSI)
- IMVT 43.58
- VCYT 68.04
- Support Level
- IMVT $14.50
- VCYT $26.61
- Resistance Level
- IMVT $15.52
- VCYT $30.63
- Average True Range (ATR)
- IMVT 0.69
- VCYT 1.18
- MACD
- IMVT -0.06
- VCYT 0.36
- Stochastic Oscillator
- IMVT 41.16
- VCYT 96.01
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.